Skip to main content
. 2018 Sep 21;19:58. doi: 10.1186/s12868-018-0460-x

Fig. 5.

Fig. 5

Pharmacological blockage of RA receptors RXR and RAR. Co-treatment with pan-retinoid-X-receptor (RXR) antagonist UVI-3003 (UVI) does not affect the anti-inflammatory effect of the combination of retinoic acid (RA) and minocycline (MINO) on TNF-α synthesis while pan-retinoic acid receptor (RAR) antagonist BMS-493 (BMS) completely impairs this anti-inflammatory mechanism. Results are presented as LPS-stimulated TNF-α, normalized for protein concentration. Values are given as mean ± SEM from at least four healthy controls in independent experiments